Journal
EUROPEAN JOURNAL OF HAEMATOLOGY
Volume 87, Issue 3, Pages 217-227Publisher
WILEY
DOI: 10.1111/j.1600-0609.2011.01649.x
Keywords
interleukin-18; rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone; diffuse large B-cell lymphoma; prognostic factor; lymphoma
Categories
Ask authors/readers for more resources
Background: We have previously reported that serum interleukin-18 (IL-18) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved. Patients and Methods: In this study, we re-evaluated the prognostic significance of serum IL-18 in 227 DLBCL patients. Seventy-three patients received CHOP before R-era, and 154 patients received rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) recently. Result: Four-year overall survival (4-yr OS) rates for patients in CHOP group with IL-18 >= 720 pg/mL and < 720 pg/mL were 8.2% and 67.3% (P < 0.0001), respectively, and 4-yr OS rates with IL-18 590 and < 590 pg/mL in R-CHOP group were 53.4% and 77.8% (P = 0.0008), respectively. Multivariate analysis revealed that serum IL-18 correlated most significantly with OS and progression-free survival (PFS) in both groups (OS: P < 0.0001, PFS: P < 0.0001, in CHOP group; OS: P = 0.0147, PFS: P = 0.0084 in R-CHOP group). The high serum IL-18 patients with poor prognostic group in revised IPI or with non-germinal center B-cell phenotype had a very poor prognosis. Conclusion: Serum IL-18 might be a powerful prognostic factor for DLBCL in R-era.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available